Intra-Cellular Therapies, Inc. (ITCI)
Market Cap | 9.08B |
Revenue (ttm) | 613.73M |
Net Income (ttm) | -86.37M |
Shares Out | 106.02M |
EPS (ttm) | -0.86 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 384,196 |
Open | 83.35 |
Previous Close | 83.35 |
Day's Range | 82.77 - 86.36 |
52-Week Range | 58.14 - 93.45 |
Beta | 0.97 |
Analysts | Strong Buy |
Price Target | 97.67 (+14.05%) |
Earnings Date | Oct 30, 2024 |
About ITCI
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of vario... [Read more]
Full Company ProfileFinancial Performance
In 2023, Intra-Cellular Therapies's revenue was $464.37 million, an increase of 85.51% compared to the previous year's $250.31 million. Losses were -$139.67 million, -45.49% less than in 2022.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for ITCI stock is "Strong Buy." The 12-month stock price forecast is $97.67, which is an increase of 14.05% from the latest price.
News
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
BEDMINSTER, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for cent...
Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress
Presentations include results from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)
Intra-Cellular's schizophrenia drug meets main goal in late-stage trial
Intra-Cellular Therapies said on Tuesday its drug to prevent relapses in schizophrenia patients met the main goal of a late-stage trial.
Intra-Cellular Therapies, Inc. (ITCI) Q3 2024 Earnings Call Transcript
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants Juan Sanchez - VP, Corporate Communications & IR Sharon Mates - Founder,...
Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance
CAPLYTA Q3 2024 net product sales were $175.2 million, compared to $125.8 million for the same period in 2023, representing a 39% increase
Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast
NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...
Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress
Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)
Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences
NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...
Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference
NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...
Intra-Cellular Therapies, Inc. (ITCI) Q2 2024 Earnings Call Transcript
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q2 2024 Earnings Conference Call August 7, 2024 8:30 AM ET Company Participants Juan Sanchez - Vice President of Corporate Communications & Investor Relat...
Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...
Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance
CAPLYTA Q2 2024 net product sales were $161.3 million, compared to $110.1 million for the same period in 2023, representing a 46% increase
Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...
Intra-Cellular Brightens MDD Outlook With Caplyta Success
Caplyta (lumateperone) shows significant promise as an adjunctive treatment for Major Depressive Disorder. Caplyta's unique pharmacological profile targeting serotonin, dopamine, and glutamate pathway...
Intra-Cellular Therapies' Highlights Successful Data From Second Depression Study
Tuesday, Intra-Cellular Therapies Inc ITCI released topline results from Study 502 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disor...
Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
In Study 502, lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints
Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...
Intra-Cellular Therapies to Present at the Jefferies Global Healthcare Conference
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervo...
Intra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervo...
Intra-Cellular Therapies, Inc. (ITCI) Q1 2024 Earnings Call Transcript
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q1 2024 Earnings Conference Call May 7, 2024 8:30 AM ET Company Participants Juan Sanchez - Vice President of Corporate Communications and Investor Relati...
Intra-Cellular Therapies Reports First Quarter 2024 Financial Results
CAPLYTA Q1 2024 net product sales were $144.8 million , compared to $94.7 million for the same period in 2023 , representing a 53% increase
Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ner...
Intra-Cellular Therapies: Positive MDD Data And Commercial Momentum Make It A Buy
The share price reaction of Intra-Cellular Therapies was not as strong as expected after the positive phase 3 results of Caplyta in major depressive disorder. Positive MDD results represent another de...
Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of...
Intra-Cellular Therapies Prices Public Offering of Common Stock
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of...